Posted on

Japanese Encephalitis Vaccine for the prevention of japanese encephalitis among children 9 to 59 months old in high-risk areas

General Track – Cycle 1 | Vaccines

HTA Council Recommendation (as of 13 June 2025)

The HTA Council positively recommends the government financing of  both live, attenuated, recombinant, vero cell; and, inactivated adsorbed, vero cell Japanese Encephalitis vaccines to be rolled out in high risk areas (as defined by DOH), contingent on the budget and resource availability. (See below for more details)

Relevant Information

  • Dosage Strength
    • Live, attenuated: one dose (0.5 mL) contains 4.0-5.8 log Plaque Forming Units (PFU) live, attenuated, recombinant Japanese Encephalitis Virus.
    • Inactivated, adsorbed: 6 mcg/0.5 mL
  • Dosage Forms:
    • Live, attenuated: Powder for Suspension for Injection (SC)
    • Inactivated, adsorbed: Suspension for Injection (IM)
  • Status: with Final HTA Council Recommendation
  • Topic Assignment: Internal Assessment
  • Policy Question: Should live, attenuated, recombinant AND/OR inactivated Japanese Encephalitis vaccine for the prevention of Japanese Encephalitis among children 9 to 59 months old be funded by the government?
  • Secretary of Health Decision:  Approved for inclusion in the Philippine National Formulary

Evidence and Relevant Documents

Back to Assessments Page